Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of efgartigimod PH20 SC in adults with bullous pemphigoid
NL-OMON56108Phase 3Completed
- Sponsor
- argenx
- Start
- Aug 2023
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of efgartigimod alfa in Bullous Pemphigoid (BP), sponsored by argenx. Primary endpoint: Incidence and severity of treatment-emergent adverse events. Started Aug 2023; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on NL-OMON56108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56108.